

**ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY**

---

**A021502 STUDY DOCUMENTS**

---

**RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB  
AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA  
MISMATCH REPAIR (ATOMIC)**

*ClinicalTrials.gov Identifier: NCT02912559*

Study Activation Date: 09/12/2017

Study Closure Date: N/A

Patient Follow-up Termination Date: N/A

<b>DOCUMENT NAME</b>	<b>EFFECTIVE DATE</b>	<b>ALLIANCE POSTING DATE</b>
Activation (NCI Version 07/13/2017) Memorandum Re: Requirements for NDA/Registration Trial	09/12/2017	09/12/2017
Update #01 (NCI Version 11/02/2017) Memorandum Re: Delegation of Task Log Activation		12/15/2017
Update #02 (NCI Version 05/08/2018) Correlative Science Manual		07/15/2018
Update #03 (NCI Version 07/09/2018) Memorandum Re: Delegation of Task Log Revision		08/01/2018
Update #04 (NCI Version 09/21/2018) Atezolizumab Action Letter Broadcast Re: Action Letter: Immediate Action Required		10/05/2018
Update #05 (NCI Version 02/05/2019)		03/01/2019
Update #06 (NCI Version 06/30/2020)		08/01/2020
Update #07 (NCI Version 10/29/2020)		12/15/2020
Update #08 (NCI Version 04/08/2021)		05/01/2021
Updated #09 (NCI Version 06/07/2021) Atezolizumab Action Letter Broadcast Re: Action Letter: Immediate Action Required		06/23/2021
Action Required 06/23/2021 Update #10 (NCI Version 10/15/2021)		12/15/2021
Update #11 (NCI Version 08/01/2022)		09/01/2022
Update #12 (NCI Version 08/25/2022)		10/01/2022
Update #13 (NCI Version 10/11/2022)		12/01/2022
Broadcast Re: Notice of Closure	1/17/2023	02/01/2023
Update #14 (NCI Version 05/23/2023)		07/14/2023